唐氏综合征患者接种严重急性呼吸综合征冠状病毒 2 疫苗后的抗体反应下降。

Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome.

机构信息

Department of Paediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.

Center of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.

出版信息

J Infect Dis. 2022 Sep 4;226(4):673-677. doi: 10.1093/infdis/jiac235.

DOI:10.1093/infdis/jiac235

PMID:35748853

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9278229/

Abstract

UNLABELLED

The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this prospective observational cohort study, SARS-CoV-2 spike S1-specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]-1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age.

CLINICAL TRIALS REGISTRATION

NCT05145348.

摘要

未标注

唐氏综合征成人感染严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的严重病程风险增加，死亡率上升了约 10 倍，特别是年龄大于 40 岁的患者。初次 SARS-CoV-2 疫苗接种后，这些较高的风险仍然存在。在这项前瞻性观察队列研究中，比较了唐氏综合征成人和健康对照者在常规 SARS-CoV-2 疫苗（BNT162b2、信使 RNA [mRNA]-1273 或 ChAdOx1）接种后的 SARS-CoV-2 刺突 S1 特异性抗体反应。2 种 mRNA 疫苗接种或 2 种 ChAdOx1 疫苗接种后，唐氏综合征成人的抗体浓度较低。接受 2 次 mRNA 疫苗接种后，抗体浓度随年龄的增加而降低。